Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Yang

Showing results (661-670 of 738) with videos related to

Pageof 74
Sort By:
Journal of Ethnopharmacology|August 30, 2023
The protective role of Achyranthes aspera extract against cisplatin-induced nephrotoxicity by alleviating oxidative stress, inflammation, and PANoptosisSong-Yi Lin, Chia-Lin Chang, Kuo-Tong Liou, et al.
Nature and Science of Sleep|August 2, 2021
Snoring Sound Characteristics are Associated with Common Carotid Artery Profiles in Patients with Obstructive Sleep ApneaHai-Hua Chuang, Chi-Hung Liu, Chao-Yung Wang, et al.
Virtual Reality|August 22, 2022
Comparison of the effect of 360° versus two-dimensional virtual reality video on history taking and physical examination skills learning among undergraduate medical students: a randomized controlled trialYi-Ping Chao, Chung-Jan Kang, Hai-Hua Chuang, et al.
Nature|May 16, 2019
Fidelity benchmarks for two-qubit gates in siliconW Huang, C H Yang, K W Chan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 3, 2018
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trialsG Goss, C-M Tsai, F A Shepherd, et al.
Anticancer Research|May 6, 1998
Momordins inhibit both AP-1 function and cell proliferationD K Lee, B Kim, S G Lee, et al.
The Lancet. Oncology|June 9, 2015
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, et al.
Nature Communications|March 24, 2011
Near-field examination of perovskite-based superlenses and superlens-enhanced probe-object couplingS C Kehr, Y M Liu, L W Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerG R Oxnard, J C-H Yang, H Yu, et al.
British Journal of Cancer|April 24, 2014
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignanciesC-C Lin, W-C Su, C-J Yen, et al.
Pageof 74

Showing results (661-670 of 738) with videos related to

Sort By:
Pageof 74
Journal of Ethnopharmacology|August 30, 2023
The protective role of Achyranthes aspera extract against cisplatin-induced nephrotoxicity by alleviating oxidative stress, inflammation, and PANoptosisSong-Yi Lin, Chia-Lin Chang, Kuo-Tong Liou, et al.
Nature and Science of Sleep|August 2, 2021
Snoring Sound Characteristics are Associated with Common Carotid Artery Profiles in Patients with Obstructive Sleep ApneaHai-Hua Chuang, Chi-Hung Liu, Chao-Yung Wang, et al.
Virtual Reality|August 22, 2022
Comparison of the effect of 360° versus two-dimensional virtual reality video on history taking and physical examination skills learning among undergraduate medical students: a randomized controlled trialYi-Ping Chao, Chung-Jan Kang, Hai-Hua Chuang, et al.
Nature|May 16, 2019
Fidelity benchmarks for two-qubit gates in siliconW Huang, C H Yang, K W Chan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 3, 2018
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trialsG Goss, C-M Tsai, F A Shepherd, et al.
Anticancer Research|May 6, 1998
Momordins inhibit both AP-1 function and cell proliferationD K Lee, B Kim, S G Lee, et al.
The Lancet. Oncology|June 9, 2015
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, et al.
Nature Communications|March 24, 2011
Near-field examination of perovskite-based superlenses and superlens-enhanced probe-object couplingS C Kehr, Y M Liu, L W Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerG R Oxnard, J C-H Yang, H Yu, et al.
British Journal of Cancer|April 24, 2014
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignanciesC-C Lin, W-C Su, C-J Yen, et al.
Pageof 74